Delayed Pseudoprogression in Glioblastoma Patients Treated With Tumor-Treating Fields

被引:0
|
作者
Saito, Norihiko [1 ]
Hirai, Nozomi [1 ]
Sato, Sho [1 ]
Hayashi, Morito [1 ]
Iwabuchi, Satoshi [1 ]
机构
[1] Toho Univ, Neurosurg, Ohashi Med Ctr, Tokyo, Japan
关键词
electric fields; glioblastoma multiforme; temozolomide; radiation therapy; pseudoprogression; ttfields; glioblastoma; TEMOZOLOMIDE; RADIOTHERAPY; BEVACIZUMAB; TRIAL;
D O I
10.7759/cureus.55147
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tumor-treating fields (TTFields) is an established treatment modality for glioblastoma. False progression to chemoradiation is a known problem in patients with glioblastoma multiforme (GBM), with most cases occurring within three months of radiation therapy. In this report, we present two cases of delayed pseudoprogression caused by TTFields. Two patients with GBM who received TTFields showed signs of radiographic progression six months after the completion of radiation therapy. Patient 1 was a 37-year-old female with a glioblastoma in the right temporal lobe. Patient 2 was a 70-year-old male with glioblastoma in the left temporal lobe. Both patients received radiation therapy, followed by temozolomide (TMZ) maintenance therapy and TTFields. Patient 1 underwent a second resection; however, the pathology revealed only a treatment effect, and the final diagnosis was a pseudoprogression. In Case 2, the disease resolved with steroid therapy alone. In both patients, the lesions appeared later than during the typical pseudoprogression period. A recent study reported that TTFields increase the permeability of the plasma cell membrane, which may result in further leakage of gadolinium into the extracellular lumen. Further studies are needed to better characterize delayed pseudoprogression and improve treatment outcomes.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial
    Cappelli, Louis
    Khan, Mehak Majid
    Kayne, Allison
    Poiset, Spencer
    Miller, Ryan
    Ali, Ayesha
    Niazi, Muneeb
    Shi, Wenyin
    Alnahhas, Iyad
    CHINESE CLINICAL ONCOLOGY, 2023, 12 (03)
  • [22] Tumor-treating fields: time for demystification
    Weller, M.
    ANNALS OF ONCOLOGY, 2018, 29 (08) : 1628 - 1630
  • [23] Efficacy and safety of tumor-treating fields in recurrent glioblastoma: a systematic review and meta-analysis
    Li, Xiaohui
    Jia, Zetian
    Yan, Yaqi
    ACTA NEUROCHIRURGICA, 2022, 164 (08) : 1985 - 1993
  • [24] The safety profile of Tumor Treating Fields (TTFields) therapy in glioblastoma patients with ventriculoperitoneal shunts
    Oberheim-Bush, Nancy Ann
    Shi, Wenyin
    McDermott, Michael W.
    Grote, Alexander
    Stindl, Julia
    Lustgarten, Leonardo
    JOURNAL OF NEURO-ONCOLOGY, 2022, 158 (03) : 453 - 461
  • [25] Concurrent Tumor-Treating Fields and Chemoradiotherapy: Outcomes in Grade 4 Glioma Patients
    Li, Jintan
    Tao, Jincheng
    Lu, Hongyu
    Fan, Xiao
    Wang, Zhichao
    Wang, Yingyi
    Wang, Xiefeng
    Yan, Wei
    You, Yongping
    Cao, Yuandong
    Zhang, Junxia
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2025, 19
  • [26] Tumor treating induced fields: a new treatment option for patients with glioblastoma
    Cai, Zehao
    Yang, Zukai
    Wang, Ying
    Li, Ye
    Zhao, Hong
    Zhao, Hanwen
    Yang, Xue
    Wang, Can
    Meng, Tengteng
    Tong, Xiao
    Zheng, Hao
    He, Zhaoyong
    Niu, Chunli
    Yang, Junzhi
    Chen, Feng
    Yang, Zhi
    Zou, Zhige
    Li, Wenbin
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [27] Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy
    Jo, Yunhui
    Kim, Eun Ho
    Sai, Sei
    Kim, Jin Su
    Cho, Jae-Min
    Kim, Hyeongi
    Baek, Jeong-Hwa
    Kim, Jeong-Yub
    Hwang, Sang-Gu
    Yoon, Myonggeun
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (11)
  • [28] Effectiveness and safety of tumor-treating fields therapy for glioblastoma: A single-center study in a Chinese cohort
    She, Lei
    Gong, Xuan
    Su, Lin
    Liu, Chao
    FRONTIERS IN NEUROLOGY, 2023, 13
  • [29] Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
    Ansstas, George
    Tran, David D.
    CASE REPORTS IN NEUROLOGY, 2016, 8 (01): : 1 - 9
  • [30] Dosimetric impact of a Tumor Treating Fields Device for glioblastoma Patients Undergoing simultaneous radiation Therapy
    Li, Taoran
    Shukla, Gaurav
    Peng, Cheng
    Lockamy, Virginia
    Liu, Haisong
    Shi, Wenyin
    FRONTIERS IN ONCOLOGY, 2018, 8